WESTPORT, Conn., Jan. 15 /PRNewswire/ -- IMS HEALTH (NYSE: RX) announced
that the two-for-one split of its common stock is effective at the close of
trading today, January 15, 1999. The stock closed on the New York Stock
Exchange at a pre-split price of $69-15/16, and will begin trading on a post-
split basis when the market opens on January 19, 1999.
IMS HEALTH shareholders of record on December 29, 1998 receive one
additional share for every share of IMS HEALTH common stock held. With the
distribution, there are approximately 320 million total IMS HEALTH shares
outstanding as of January 15.
IMS HEALTH is the world's leading provider of information solutions to the
pharmaceutical and healthcare industries. With more than $1 billion in 1997
revenue, IMS HEALTH operates in over 90 countries. IMS HEALTH is the largest
pharmaceutical manufacturer information partner, with over 40 years'
experience in the industry. Key products and services integral to customer
day-to-day operations include: market research for prescription and over-the-
counter pharmaceutical products; sales management information to optimize
sales force productivity; technology enabled selling solutions for sales and
marketing decision-making; and technology systems and information services
that support managed care organizations. Additional information is available
at http://www.imshealth.com.
This press release includes statements which may constitute forward-
looking statements made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Although IMS HEALTH believes the
expectations contained in such forward-looking statements are reasonable, it
can give no assurance that such expectations will prove correct. This
information may involve risks and uncertainties that could cause actual
results of IMS HEALTH to differ materially from the forward-looking
statements. Factors which could cause or contribute to such differences
include, but are not limited to (i) the risks associated with operating on a
global basis, including fluctuations in the value of foreign currencies
relative to the U.S. dollar, and the ability to successfully hedge such risks,
(ii) the extent in which IMS HEALTH seeks growth through acquisitions, and the
ability to identify and consummate acquisitions on satisfactory terms, (iii)
the ability to develop new or advanced technologies and systems for its
businesses on a cost-effective basis, (iv) regulatory and legislative
initiatives, particularly in the area of medical privacy, and (v)
deterioration in economic conditions, particularly in the pharmaceutical,
healthcare, information technology or other industries in which IMS HEALTH's
customers operate.
SOURCE IMS HEALTH
 back to top
Related links:
http://www.imshealth.com
Company News On-Call:
http://www.prnewswire.com/comp/115785.html or fax,
800-758-5804, ext. 115785
CONTACT:
Michael Gury of IMS HEALTH, 203-222-4230
|
